Back to results
US 2022/0009916 A1Published application
Acetylation writer inhibitor development and uses thereof
AssigneeDana-Farber Cancer Institute, Inc.
InventorsJun Qi, Adam D. Durbin
Life of this patent
Estimating the term…
Abstract
Disclosed are bifunctional compounds (degraders) that target HAT EP300 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.
Claims38
A bifunctional compound having a structure represented by formula I:
- wherein the targeting ligand represents a moiety that binds histone acetyltransferase (HAT) EP300, the degron represents a moiety that binds an E3 ubiquitin ligase, and the linker represents a moiety that covalently connects the degron and the targeting ligand, or a pharmaceutically acceptable salt or stereoisomer thereof.
-5. (canceled)
-16. (canceled)
A bifunctional compound having a structure represented by formula II:
- wherein the targeting ligand represents a moiety that binds histone acetyltransferase p300, the linker represents a moiety that covalently connects biotin and the targeting ligand, or a pharmaceutically acceptable salt or stereoisomer thereof.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.